The experimental Alzheimer’s drug gantenerumab is the “first and only” anti-amyloid antibody being investigated for subcutaneous administration and could potentially be given to patients...
Participants who took donanemab for 76 weeks showed 32% slower decline in thinking and daily function compared with those in a placebo group.
Repetitive negative thinking is linked to cognitive decline and brain deposits seen in early Alzheimer’s disease, a new study has found.
Screening data from an Alzheimer’s drug trial suggests that higher brain amyloid levels exist well before clinical symptoms appear.
Older adults who drank one to 13 standard drinks a week over many years had a 66% lower rate of beta amyloid deposits, as shown in brain scans.
A blood test that helps to detect early Alzheimer’s disease is one step closer to clinical use. Its accuracy and low cost are game changers, researchers say.
Seniors will not be able to receive Medicare coverage for imaging scans to help diagnose Alzheimer’s disease, the Centers for Medicare & Medicaid Services recently announced.
Certain widely prescribed medications can trigger or slow the progress of Alzheimer’s disease, according to recently published research.
A major breakthrough in Alzheimer’s research could lead to new and more effective ways of treating the disease, according to a recently released study in the Journal of Neuroscience.
Please login or register first to view this content.